1. DC-CIK combined with chemotherapy on the efficacy, immune function, and life quality in colorectal cancer patients after radical resection
- Author
-
Lu, Dan, Li, Ting, Yang, Zhiqian, Zhao, Xin, Su, Yingying, and Nian, Liang
- Subjects
Original Article - Abstract
Objective: To investigate the efficacy of combined treatment of dendritic cell-cytokine-induced killer cells (DC-CIK) and chemotherapy on colorectal cancer (CRC) patients who have undergone radical resection, and its effect on immune function and quality of life. Methods: Data of 103 CRC patients after radical resection admitted to Xianyang First People’s Hospital and Yanan University Affiliated Hospital from March 2018 to March 2020 were retrospectively analyzed. A total of 50 patients treated with XELOX chemotherapy were included in the control group (CG). The remaining 53 patients treated with XELOX chemotherapy combined with DC-CIK were included in the observation group (OG). The therapeutic efficacy, immune function indicators, serum tumor markers before and after the treatment, adverse reactions, 2-year survival rate, and quality of life 6 months after the treatment were observed and compared between the two groups. Results: The OG was identified to have a better therapeutic effect than the CG (P0.05). The quality of life six months after the treatment and the 2-year survival rate in the OG were significantly higher than those in the CG (P
- Published
- 2023